Expert Interview
Discussing Akero's recent announcement of their Phase 2b SYMMETRY study results evaluating efruxifermin (EFX) in patients with compensated cirrhosis due to NASH
Ticker(s): AKRO, MDGL, ENTB, VKTXInstitution: GIS
- Currently manages 220 NASH pts
- Familiar with Phase 2 and 3 data for Madirgal's resmetirom announced earlier this year.
- Gastroenterology Specialist in Providence, RI and has over 38 years of experience in the medical field. Dr. Harmatz has extensive experience in Esophageal Disorders and Liver Disease.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
